Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. But with promising early results from a phase 3 study in certain ...

As has been the case for several quarters now, Merck KGaA’s life science business continues to serve as a weathervane for the broader biopharma industry. For the full year, Merck now expects ...

FDA approved Merck's Welireg as the first oral therapy for advanced pheochromocytoma or paraganglioma (PPGL). In the LITESPARK-015 trial, Welireg showed a 26% ORR and a 20.4-month median duration ...

First it was Panasonic—now, another major company is planting deeper roots in De Soto. Merck Animal Health has announced an expansion of its De Soto operations, and it’s bringing hundreds of ...

May 14 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's (MRK.N), opens new tab cancer drug to treat two rare types of adrenal gland ...

Keytruda plus chemo showed meaningful PFS improvement in all patients, regardless of PD-L1 status. Overall survival benefit observed in PD-L1–positive tumors (CPS ≥1) compared to placebo-based ...

Volker Buß joined the German multinational science and technology company Merck Group in 2021. Merck is present in more than 60 countries and employs more than 60,000 people worldwide.

Germany’s Merck MRK-6.82%decrease; red down pointing triangle KGaA shares dropped after the company slashed its full-year outlook on the back of uncertainty around tariffs and foreign-exchange ...

"I must say it's always impressive to come back to China and witness its significant and rapid transformation happening over time," said Marc Horn, EVP of Merck Group and president of Merck China ...

(Reuters) -The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's cancer drug to treat two types adrenal gland tumors. The drug, Welireg, became the ...

(RTTNews) - Merck KGaA (MKGAY.PK), a German science and technology company, Thursday reported higher profit and sales in its first quarter. Further, the firm trimmed its forecast for fiscal 2025 ...

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...